Wei Ran, Dean Dylan C, Thanindratarn Pichaya, Hornicek Francis J, Guo Wei, Duan Zhenfeng
Musculoskeletal Tumor Center, Beijing Key Laboratory of Musculoskeletal Tumor, Peking University People's Hospital, Beijing, China.
Sarcoma Biology Laboratory, Department of Orthopedic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.
Front Oncol. 2020 Nov 17;10:596330. doi: 10.3389/fonc.2020.596330. eCollection 2020.
Chordomas are rare, slow-growing sarcomas without any accepted prognostic biomarkers. Owing to their proximity to critical neurovascular structures, discovering predictive biomarkers in chordoma has been a significant research effort because it may potentially reduce risky therapies in patients with less aggressive tumors. In response, because cyclin E1 overexpression correlates with patient prognosis in several malignancies, we investigated its expression in chordoma and whether it informs patient prognosis.
Seventy-five chordoma patient specimens were enrolled in a tissue microarray (TMA) to evaluate cyclin E1 expression immunohistochemical staining. Western blot was used to assess cyclin E1 expression in chordoma cell lines and fresh tissues. We then correlated cyclin E1 staining intensity in the TMA to clinicopathological features and chordoma patient outcomes.
Sixty-three percent of the chordoma patient specimens in the TMA, fifty-six percent of the fresh chordoma tissues, and all chordoma cell lines showed high cyclin E1 expression. In TMA analysis, cyclin E1 expression positively correlated to chordoma patient disease status. By survival analysis, high cyclin E1 expression was an independent prognostic risk factor for chordoma patients along with advanced disease status and positive surgical margin.
Cyclin E1 is a promising biomarker predicting chordoma patient prognosis.
脊索瘤是一种罕见的、生长缓慢的肉瘤，目前尚无公认的预后生物标志物。由于其靠近关键的神经血管结构，在脊索瘤中发现预测性生物标志物一直是一项重要的研究工作，因为这可能会减少对侵袭性较小肿瘤患者的风险治疗。因此，鉴于细胞周期蛋白E1（cyclin E1）过表达与多种恶性肿瘤患者的预后相关，我们研究了其在脊索瘤中的表达情况以及它是否能为患者预后提供信息。
将75例脊索瘤患者的标本纳入组织芯片（TMA），以评估细胞周期蛋白E1的表达情况——采用免疫组化染色。使用蛋白质免疫印迹法评估细胞周期蛋白E1在脊索瘤细胞系和新鲜组织中的表达。然后，我们将TMA中细胞周期蛋白E1的染色强度与临床病理特征及脊索瘤患者的预后相关联。
TMA中63%的脊索瘤患者标本、56%的新鲜脊索瘤组织以及所有脊索瘤细胞系均显示细胞周期蛋白E1高表达。在TMA分析中，细胞周期蛋白E1的表达与脊索瘤患者的疾病状态呈正相关。通过生存分析，细胞周期蛋白E1高表达是脊索瘤患者的一个独立预后危险因素，同时还有疾病进展和手术切缘阳性。
细胞周期蛋白E1是一种很有前景的预测脊索瘤患者预后的生物标志物。
